Apigenin 7-O-methylglucuronideCAS# 53538-13-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 53538-13-9 | SDF | Download SDF |
PubChem ID | 13844658 | Appearance | Yellow powder |
Formula | C22H20O11 | M.Wt | 460.4 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | methyl (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylate | ||
SMILES | COC(=O)C1C(C(C(C(O1)OC2=CC(=C3C(=C2)OC(=CC3=O)C4=CC=C(C=C4)O)O)O)O)O | ||
Standard InChIKey | XXKIWCKZQFBXIR-SXFAUFNYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, may potentially be used in osteogenesis imperfecta (OI) type I pharmacotherapy in patients with normal GAG content. 2. Apigenin 7-O-methylglucuronide which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling. |
Apigenin 7-O-methylglucuronide Dilution Calculator
Apigenin 7-O-methylglucuronide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.172 mL | 10.8601 mL | 21.7202 mL | 43.4405 mL | 54.3006 mL |
5 mM | 0.4344 mL | 2.172 mL | 4.344 mL | 8.6881 mL | 10.8601 mL |
10 mM | 0.2172 mL | 1.086 mL | 2.172 mL | 4.344 mL | 5.4301 mL |
50 mM | 0.0434 mL | 0.2172 mL | 0.4344 mL | 0.8688 mL | 1.086 mL |
100 mM | 0.0217 mL | 0.1086 mL | 0.2172 mL | 0.4344 mL | 0.543 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Luteolin-3-O-beta-D-glucuronide
Catalog No.:BCN3826
CAS No.:53527-42-7
- Durantoside I
Catalog No.:BCN4621
CAS No.:53526-67-3
- Durantoside II
Catalog No.:BCN4622
CAS No.:53526-66-2
- 7-Amino-4-(Trifluoromethyl)Coumarin
Catalog No.:BCC9208
CAS No.:53518-15-3
- 4,9,9'-Trihydroxy-3,3'-dimethoxy-8,4'-oxyneolignan
Catalog No.:BCN1425
CAS No.:53505-68-3
- PIT 1
Catalog No.:BCC7873
CAS No.:53501-41-0
- Marein
Catalog No.:BCN6477
CAS No.:535-96-6
- Trigonelline
Catalog No.:BCN2371
CAS No.:535-83-1
- Pipecolinic acid
Catalog No.:BCN8150
CAS No.:535-75-1
- Apohyoscine
Catalog No.:BCN1870
CAS No.:535-26-2
- 4-Methoxycinnamyl alcohol
Catalog No.:BCN7515
CAS No.:53484-50-7
- Creticoside C
Catalog No.:BCN5707
CAS No.:53452-34-9
- Benzoyl-L-histidine
Catalog No.:BCC8866
CAS No.:5354-94-9
- Diaveridine
Catalog No.:BCC8936
CAS No.:5355-16-8
- (-)-Bicuculline methochloride
Catalog No.:BCN3763
CAS No.:53552-05-9
- Beta-Amyrenonol acetate
Catalog No.:BCN4620
CAS No.:5356-56-9
- 5-Galloylquinic acid
Catalog No.:BCN3060
CAS No.:53584-43-3
- H-Tyr-OBzl.TosOH
Catalog No.:BCC3124
CAS No.:53587-11-4
- Secolongifolenediol
Catalog No.:BCN6989
CAS No.:53587-37-4
- 5'-Iodoresiniferatoxin
Catalog No.:BCC7031
CAS No.:535974-91-5
- Ethionamide
Catalog No.:BCC3778
CAS No.:536-33-4
- Perillyl alcohol
Catalog No.:BCN3876
CAS No.:536-59-4
- 1-Hydroxyrutaecarpine
Catalog No.:BCN5709
CAS No.:53600-24-1
- GMQ hydrochloride
Catalog No.:BCC6351
CAS No.:5361-15-9
Differential effect of flavonoids on glycosaminoglycan content and distribution in skin fibroblasts of patients with type I osteogenesis imperfecta.[Pubmed:21472276]
Mol Med Rep. 2010 May-Jun;3(3):537-41.
We recently reported that, in osteogenesis imperfecta (OI) type I with diminished type I collagen biosynthesis, flavonoids such as apigenin 7-O-glucuronide, Apigenin 7-O-methylglucuronide and pectolinarin normalized the level of collagen type I without affecting total protein synthesis. In addition to collagen, glycosaminoglycans (GAGs) play an important role in the formation of a functional supramolecular complex in the extracellular matrix, and any changes in their content and/or composition may be involved in the OI phenotype. We previously detected a marked increase in sulphated GAG content in the OI fibroblasts of more severely affected patients (OI types II and III). These alterations were more pronounced in medium than in cells. Although, in OI type I cells, the increase observed in medium was much smaller (approximately 1.5-fold), it resulted in an increase of approximately 3-fold of the GAG to collagen type I ratio. Therefore, in the potential pharmacotherapy of OI type I with flavonoids, their effect on GAG level may be of importance. In the OI cells, some of the tested flavonoids applied at a concentration of 30 microM affected GAG content in quite the opposite way than type I collagen. Aglicones inhibiting collagen synthesis caused a marked increase in GAG concentration in medium, in contrast to the flavonoid glycosides, which exerted a stimulatory effect on type I collagen synthesis, but had a different effect on GAG content and distribution. Among these, Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, and thus may potentially be used in OI type I pharmacotherapy in patients with normal GAG content. However, in patients with increased concentrations of GAG, pectolinarin, which decreases GAG content by approximately 40%, may be more beneficial.
Stimulation of collagen biosynthesis by flavonoid glycosides in skin fibroblasts of osteogenesis imperfecta type I and the potential mechanism of their action.[Pubmed:17982699]
Int J Mol Med. 2007 Dec;20(6):889-95.
The aim of the present study was to identify bioactive compounds stimulating collagen biosynthesis with potential for osteogenesis imperfecta (OI) type I pharmacological therapy. Of the compounds tested, apigenin glycosides 7-O-glucuronide, 7-O-methylglucuronide and pectolinarin at 30 microM were found to significantly induce collagen type I synthesis in OI fibroblasts without an effect on the overall protein synthesis. None of the compounds displayed any toxicity at that concentration. Secretion of collagen into media was not affected by apigenin 7-O-glucuronide and was slightly increased in cells treated with Apigenin 7-O-methylglucuronide and pectolinarin. Furthermore, procollagen secreted by treated cells underwent a more rapid processing into collagen as compared with control untreated cells. In addition, we elucidated the possible mechanism involved in their action. Stimulation of collagen biosynthesis was not due to an increase in cell proliferation, because no differences in DNA content between the compound-treated and untreated cells were observed. Since flavonoids are known as strong inhibitors of metalloproteinases degrading matrix proteins, the increased level of collagen could result from the inhibition of their activity. However, the compounds with a stimulatory effect on collagen synthesis did not influence the activities of collagenase type I, gelatinases A and B, and stromelysin. On the contrary, all compounds stimulated the activity of prolidase which catalyzes the final step of collagen degradation and plays an important role in collagen biosynthesis. Stimulation of collagen synthesis and prolidase activity by apigenin 7-O-glucuronide was accompanied by an increase in IGF-I receptor expression. In contrast, the compounds Apigenin 7-O-methylglucuronide and pectolinarin which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling.